AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23471234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial bradykinin infusion with enalapril
Number of subjects: 20
Study 20973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 1504
Study 20973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1504
Study 20973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 1504
Study 20973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR + nicotine lozenge
Number of subjects: 1504
Study 20973856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch + nicotine lozenge
Number of subjects: 1504
Study 20973856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1504
Study 18959640 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation (CO2i)
Number of subjects: 96
Study 18959640 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation (AIRi)
Number of subjects: 96
Study 16099023 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere sensitivity to orthographic variables
Number of subjects: 1
Study 16099023 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere sensitivity to orthographic variables
Number of subjects: 1
Study 16099023 — intervention group
Group type: COMPARATOR
Intervention: Dyslexia group
Number of subjects: 1
Study 16099023 — intervention group
Group type: COMPARATOR
Intervention: Normal readers
Number of subjects: 1
Study 12869836 — intervention group
Group type: EXPERIMENTAL
Intervention: BufferGel
Number of subjects: 97
Study 12869836 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO 2000 Gel
Number of subjects: 97
Study 12869836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (K-Y Jelly)
Number of subjects: 97
Study 12869836 — intervention group
Group type: EXPERIMENTAL
Intervention: BufferGel and PRO 2000 Gel
Number of subjects: 97
Study 11031076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solutions (2 and 5% NaCl) and thirsting
Number of subjects: 8
Study 11031076 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking of free water and overnight application of desmopressin
Number of subjects: 8
Study 11031076 — intervention group
Group type: COMPARATOR
Intervention: Oral water ad libitum
Number of subjects: 8
Study 9100162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (600 lipoprotein-lipase releasing units, intramuscularly, daily for 28 days)
Number of subjects: 15
Study 8261692 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg od
Number of subjects: 148
Study 8261692 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine PT 2.5 mg bid
Number of subjects: 148
Study 8261692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 3511691 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 62
Study 3511691 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 62
Study 30041437 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein diet with three whole eggs per day (1.4 g protein kg‐1 day‐1)
Number of subjects: 22
Study 30041437 — intervention group
Group type: COMPARATOR
Intervention: Normal-Protein diet void of eggs (0.8 g protein kg‐1 day‐1)
Number of subjects: 22
Study 27936999 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pill irbesartan/amlodipine combination-based therapy for 12 weeks
Number of subjects: 20
Study 25166215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygopalatine fossa injection with 1% xylocaine and 1:100,000 adrenaline
Number of subjects: 45
Study 25166215 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral side without injection)
Number of subjects: 45
Study 22651920 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing the film with contextual information
Number of subjects: 0
Study 22651920 — intervention group
Group type: COMPARATOR
Intervention: Viewing the film without contextual information
Number of subjects: 0
Study 19238327 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin 4.5 g/day
Number of subjects: 36
Study 19238327 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin 9 g/day
Number of subjects: 36
Study 18496751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal care for high-risk mothers
Number of subjects: 0
Study 18496751 — intervention group
Group type: COMPARATOR
Intervention: Prenatal care for low-risk mothers
Number of subjects: 0
Study 18547273 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal levodopa/carbidopa infusion
Number of subjects: 18
Study 18547273 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 18
Study 15383088 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat-to-beat pulse pressure (PP) variability
Number of subjects: 150
Study 11442859 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 56
Study 11442859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal Tube (TT)
Number of subjects: 56
Study 11442859 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Mask (FM)
Number of subjects: 56
Study 9228961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural training (CBT)
Number of subjects: 289
Study 9228961 — intervention group
Group type: COMPARATOR
Intervention: Control programme
Number of subjects: 289
Study 7913683 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐adrenoceptor antagonists (beta AA)
Number of subjects: 737
Study 7913683 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium channel blockers (CCB)
Number of subjects: 737
Study 7913683 — intervention group
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA)
Number of subjects: 737
Study 30001179 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval-warning group
Number of subjects: 0
Study 30001179 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval-warning group with positive mood
Number of subjects: 0
Study 30001179 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval-warning group with negative mood
Number of subjects: 0
Study 30001179 — intervention group
Group type: COMPARATOR
Intervention: No-warning group
Number of subjects: 0
Study 30346878 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographs created for the research project to match the three populations (Real Health Photos - RHP)
Number of subjects: 1796
Study 30346878 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages with only half of the matched RHP images
Number of subjects: 1796
Study 30346878 — intervention group
Group type: COMPARATOR
Intervention: Photographs from a stock photograph service
Number of subjects: 1796
Study 26946730 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple acupuncture method at cervical Jiaji (EX-B 2)
Number of subjects: 66
Study 26946730 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 66
Study 24318863 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned treatment preceded by pretreatment genetic analysis
Number of subjects: 53
Study 24318863 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen in planned treatment group
Number of subjects: 53
Study 24318863 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen in planned treatment group
Number of subjects: 53
Study 24318863 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 53
Study 24318863 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX regimen in conventional treatment group
Number of subjects: 53
Study 24318863 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI regimen in conventional treatment group
Number of subjects: 53
Study 22222326 — intervention group
Group type: EXPERIMENTAL
Intervention: Imbalanced asymmetrical center of mass condition (20-kg plate on one side and sixteen 1.25-kg plates on the other side)
Number of subjects: 35
Study 22222326 — intervention group
Group type: COMPARATOR
Intervention: Balanced condition (one 20-kg plate on each side)
Number of subjects: 35
Study 22222326 — intervention group
Group type: COMPARATOR
Intervention: Imbalanced asymmetrical condition (one 20-kg plate on one side and one 20-kg plate plus a 1.25-kg plate on the other side)
Number of subjects: 35
Study 20358168 — intervention group
Group type: EXPERIMENTAL
Intervention: Active shock wave stimulation
Number of subjects: 12
Study 20358168 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 12
Study 17408924 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral clindamycin (600 mg) administered preoperatively
Number of subjects: 86
Study 17408924 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin administered preoperatively with continued therapy for 5 days
Number of subjects: 86
Study 17408924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17408924 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral clindamycin (600 mg)
Number of subjects: 86
Study 17408924 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (single dose or 5-day therapy)
Number of subjects: 86
Study 16306824 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaket
Number of subjects: 45
Study 16306824 — intervention group
Group type: COMPARATOR
Intervention: AH Plus
Number of subjects: 45
Study 16306824 — intervention group
Group type: COMPARATOR
Intervention: EndoREZ
Number of subjects: 45
Study 11893841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (Exelon)
Number of subjects: 92
Study 11893841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 10205637 — intervention group
Group type: EXPERIMENTAL
Intervention: Folifer-Z tablets
Number of subjects: 30
Study 10205637 — intervention group
Group type: COMPARATOR
Intervention: Fefol-Z capsules
Number of subjects: 30
Study 7697305 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment as an intervention
Number of subjects: 0
Study 7697305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' experiences in quality-of-life assessment
Number of subjects: 0
Study 2472826 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (streptozotocin plus 5-fluorouracil)
Number of subjects: 30
Study 2472826 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogue SMS 201-995
Number of subjects: 30
Study 2472826 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 30
Study 2472826 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-1/2 (2b) or IntronA
Number of subjects: 30
Study 48191 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli 075:K100:H5
Number of subjects: 16
Study 31718427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofia 6‐French PLUS catheter
Number of subjects: 54
Study 31537372 — intervention group
Group type: EXPERIMENTAL
Intervention: MAISHA intervention (10 sessions)
Number of subjects: 1049
Study 31537372 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-listed for intervention)
Number of subjects: 1049
Study 28533200 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about Medicines Questionnaire (quantitative assessment)
Number of subjects: 196
Study 28533200 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews (thematic analysis)
Number of subjects: 196
Study 26522042 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro XT light-curable fluoride varnish applied to buccal surfaces adjacent to brackets
Number of subjects: 38
Study 26522042 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study 26522042 — intervention group
Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 38
Study 23053214 — intervention group
Group type: EXPERIMENTAL
Intervention: Roll-plate technique
Number of subjects: 199
Study 23053214 — intervention group
Group type: COMPARATOR
Intervention: Sonication technique
Number of subjects: 199
Study 23053214 — intervention group
Group type: COMPARATOR
Intervention: Urine culture
Number of subjects: 199
Study 20528216 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 μg per day)
Number of subjects: 166
Study 20528216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 19408858 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorheopheresis (cascade filtration), 8 cycles in 10 weeks
Number of subjects: 32
Study 19408858 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural course of ARMD)
Number of subjects: 32
Study 17536122 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate multivitamin and mineral supplementation (vitamin C 150.0 mg/day, vitamin E 24.0 mg/day, beta-carotene 4.8 mg/day)
Number of subjects: 17
Study 17536122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15779316 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + SB
Number of subjects: 45
Study 15779316 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + PB
Number of subjects: 45
Study 15779316 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + CSE
Number of subjects: 45
Study 15779316 — intervention group
Group type: COMPARATOR
Intervention: SB
Number of subjects: 45
Study 15779316 — intervention group
Group type: COMPARATOR
Intervention: PB
Number of subjects: 45
Study 15779316 — intervention group
Group type: COMPARATOR
Intervention: CSE
Number of subjects: 45
Study 16144560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 67
Study 16144560 — intervention group
Group type: COMPARATOR
Intervention: Autologous fascia lata (Lata)
Number of subjects: 67
Study 11376277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of SH U 508A (1 mL/min)
Number of subjects: 12
Study 11376277 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of SH U 508A
Number of subjects: 12
Study 11376277 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized infusion of SH U 508A
Number of subjects: 12
Study 9231473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic eradication of Helicobacter Pylori
Number of subjects: 0
Study 9231473 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8433354 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection behaviors (e.g., cholesterol check)
Number of subjects: 0
Study 8433354 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion behaviors (e.g., eating a low-fat diet)
Number of subjects: 0
Study 8433354 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and emotional persuasive messages
Number of subjects: 0
Study 3691441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm formaldehyde (FA) exposure for 40 min with mild exercise regimen (450 kpm/min) after 5 min in chamber
Number of subjects: 15
Study 3691441 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm formaldehyde (FA) exposure for 40 min
Number of subjects: 15
Study 3691441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm formaldehyde (FA) exposure with symptom diary and PEFR measurements recorded for 24 hr after exposure
Number of subjects: 15
Study 29843755 — intervention group
Group type: EXPERIMENTAL
Intervention: G + MK (gemcitabine + MK-0646)
Number of subjects: 45
Study 29843755 — intervention group
Group type: EXPERIMENTAL
Intervention: G + MK + E (gemcitabine + MK-0646 + erlotinib)
Number of subjects: 45
Study 29843755 — intervention group
Group type: COMPARATOR
Intervention: G + E (gemcitabine + erlotinib)
Number of subjects: 45
Study 26024744 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management program with telephone follow-up sessions
Number of subjects: 0
Study 26024744 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 25592781 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN and low doses of MTX
Number of subjects: 377
Study 25592781 — intervention group
Group type: COMPARATOR
Intervention: IFN and all trans-retinoid acid
Number of subjects: 377
Study 23418958 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiovascular treatment according to Dutch guidelines
Number of subjects: 179
Study 23418958 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling based on self-monitoring (pedometer, weighing scale and/or blood pressure device) by trained practice nurses
Number of subjects: 179
Study 22029856 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 mcg
Number of subjects: 25
Study 22029856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18203182 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 23
Study 18203182 — intervention group
Group type: COMPARATOR
Intervention: ECMO
Number of subjects: 23
Study 18203182 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (CM)
Number of subjects: 23
Study 16995545 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized aspheric treatment zone (CATz)
Number of subjects: 27
Study 16995545 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 27
Study 14722370 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (60 mg)
Number of subjects: 244
Study 14722370 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly iron supplementation (60 mg)
Number of subjects: 244
Study 11398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutrophic newborns group (33 women)
Number of subjects: 99
Study 11398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotrophic newborns group (36 women)
Number of subjects: 99
Study 11398594 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy not pregnant women)
Number of subjects: 99
Study 9163024 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) on cerebrospinal fluid (CSF) and brain samples
Number of subjects: 260
Study 9163024 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment with aciclovir
Number of subjects: 260
Study 1351888 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg once daily for 4 weeks
Number of subjects: 32
Study 1351888 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 6584561 — intervention group
Group type: EXPERIMENTAL
Intervention: Carminomycin (18 mg/m2)
Number of subjects: 63
Study 6584561 — intervention group
Group type: COMPARATOR
Intervention: 4'-epidoxorubicin (90 mg/m2)
Number of subjects: 63
Study 30391573 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with 45 Gy/30 twice-daily fractions over 19 days
Number of subjects: 490
Study 30391573 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy with 66 Gy/33 once-daily fractions over 45 days
Number of subjects: 490
Study 30391573 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (both groups)
Number of subjects: 490
Study 29031390 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (280mg DHA and 110mg EPA)
Number of subjects: 420
Study 29031390 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 420
Study 25654629 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized program including exercise therapy plus risk factor modification for 12 weeks
Number of subjects: 53
Study 25654629 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps strengthening exercise only for 12 weeks
Number of subjects: 53
Study 23108015 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listening to music once a day for 4 consecutive weeks using two types of CDs)
Number of subjects: 60
Study 23108015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 60
Study 20880729 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 18
Study 20880729 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg plus placebo
Number of subjects: 18
Study 19781096 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous case management intervention
Number of subjects: 842
Study 19781096 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 842
Study 17542814 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care with the father
Number of subjects: 29
Study 17542814 — intervention group
Group type: COMPARATOR
Intervention: Cot care (control)
Number of subjects: 29
Study 15235556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine combined with sufentanil at a dose of 0.5 microg/ml(‐1) (group A)
Number of subjects: 45
Study 15235556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine combined with sufentanil at a dose of 0.75 microg/ml(‐1) (group B)
Number of subjects: 45
Study 15235556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine combined with sufentanil at a dose of 1 microg/ml(‐1) (group C)
Number of subjects: 45
Study 12390994 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with meconium stained amniotic fluid
Number of subjects: 0
Study 12390994 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10213522 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol exposure
Number of subjects: 86
Study 7844872 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve decompression surgery
Number of subjects: 244
Study 7844872 — intervention group
Group type: COMPARATOR
Intervention: Careful follow-up
Number of subjects: 244
Study 2169378 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration maintained at 4.5 mmol/l (euglycaemia)
Number of subjects: 10
Study 2169378 — intervention group
Group type: COMPARATOR
Intervention: Blood glucose concentration maintained at 3.5 mmol/l (mild hypoglycaemia)
Number of subjects: 10
Study 224997 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cyclophosphamide, doxorubicin, and imidazole carboximide)
Number of subjects: 288
Study 224997 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 288
Study 224997 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cycle-active therapy (vincristine, hydroxyurea, and methotrexate)
Number of subjects: 288